Welcome to Markets Desk, your midday read on the stories moving money.
AstraZeneca is having a strong session after full trial data on its COPD drug reinforced blockbuster expectations. Two late-stage wins now back the company's own peak sales forecast of more than five billion dollars annually, putting this squarely in the category of pipeline drugs that can genuinely move the needle for a major pharma.
Shifting to currencies, the yen has climbed to a six-month high against the dollar and analysts say the move may have further to run. The drivers are layered — a carry trade unwind, pressure on U.S. Treasury holdings, and improving Japanese fundamentals all pointing in the same direction. That combination tends to be sticky, and dollar-yen watchers are paying close attention.
And in fintech, Visa is expanding its data services for blockchain-based lenders as demand for stablecoin-linked payment cards continues to surge. The program gives card issuers access to credit infrastructure tied to digital assets, a signal that traditional payment rails are no longer sitting on the sidelines of the crypto economy — they are actively building into it.
That's the tape. Markets Desk, signing off the floor.
